Effect of ancient Khorasan wheat on gut microbiota, inflammation, and short-chain fatty acid production in patients with fibromyalgia.
Ancient wheat
Fibromialgya
Fibromialgya symptoms
Gut microbiota
Khorasan wheat
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 May 2022
14 May 2022
Historique:
received:
26
11
2021
revised:
19
01
2022
accepted:
27
03
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
Fibromyalgia (FM) syndrome is mainly characterized by widespread pain, sleeping disorders, fatigue, and cognitive dysfunction. In many cases, gastrointestinal distress is also reported, suggesting the potential pathogenic role of the gut microbiota (GM). The GM is deeply influenced by several environmental factors, especially the diet, and recent findings highlighted significant symptom improvement in FM patients following various nutritional interventions such as vegetarian diet, low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols based diets, gluten-free diet, and especially an ancient grain supplementation. In particular, a recent study reported that a replacement diet with ancient Khorasan wheat led to an overall improvement in symptom severity of FM patients. To examine the effects of ancient Khorasan wheat on the GM, inflammation, and short-chain fatty acid production in FM patients. After a 2-wk run-in period, 20 FM patients were enrolled in this randomized, double-blind crossover trial. In detail, they were assigned to consume either Khorasan or control wheat products for 8 wk and then, following an 8-wk washout period, crossed. Before and after treatments, GM characterization was performed by 16S rRNA sequencing while the fecal molecular inflammatory response and the short-chain fatty acids (SCFAs) were respectively determined with the Luminex MAGPIX detection system and a mass chromatography-mass spectrometry method. The Khorasan wheat replacement diet, in comparison with the control wheat diet, had more positive effects on intestinal microbiota composition and on both the fecal immune and SCFAs profiles such as the significant increase of butyric acid levels ( The replacement diet based on ancient Khorasan wheat results in beneficial GM compositional and functional modifications that positively correlate with an improvement of FM symptomatology.
Sections du résumé
BACKGROUND
BACKGROUND
Fibromyalgia (FM) syndrome is mainly characterized by widespread pain, sleeping disorders, fatigue, and cognitive dysfunction. In many cases, gastrointestinal distress is also reported, suggesting the potential pathogenic role of the gut microbiota (GM). The GM is deeply influenced by several environmental factors, especially the diet, and recent findings highlighted significant symptom improvement in FM patients following various nutritional interventions such as vegetarian diet, low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols based diets, gluten-free diet, and especially an ancient grain supplementation. In particular, a recent study reported that a replacement diet with ancient Khorasan wheat led to an overall improvement in symptom severity of FM patients.
AIM
OBJECTIVE
To examine the effects of ancient Khorasan wheat on the GM, inflammation, and short-chain fatty acid production in FM patients.
METHODS
METHODS
After a 2-wk run-in period, 20 FM patients were enrolled in this randomized, double-blind crossover trial. In detail, they were assigned to consume either Khorasan or control wheat products for 8 wk and then, following an 8-wk washout period, crossed. Before and after treatments, GM characterization was performed by 16S rRNA sequencing while the fecal molecular inflammatory response and the short-chain fatty acids (SCFAs) were respectively determined with the Luminex MAGPIX detection system and a mass chromatography-mass spectrometry method.
RESULTS
RESULTS
The Khorasan wheat replacement diet, in comparison with the control wheat diet, had more positive effects on intestinal microbiota composition and on both the fecal immune and SCFAs profiles such as the significant increase of butyric acid levels (
CONCLUSION
CONCLUSIONS
The replacement diet based on ancient Khorasan wheat results in beneficial GM compositional and functional modifications that positively correlate with an improvement of FM symptomatology.
Identifiants
pubmed: 35664958
doi: 10.3748/wjg.v28.i18.1965
pmc: PMC9150053
doi:
Substances chimiques
Fatty Acids, Volatile
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1965-1980Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no competing interests for this article.
Références
J Pers Med. 2021 Jan 08;11(1):
pubmed: 33429936
Biochim Biophys Acta. 2014 Oct;1842(10):1981-1992
pubmed: 24882755
Arthritis Rheum. 2006 Aug;54(8):2656-64
pubmed: 16871547
Biomedicines. 2020 Jul 17;8(7):
pubmed: 32709082
Cureus. 2020 Sep 6;12(9):e10276
pubmed: 33042712
Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26482-26493
pubmed: 33020290
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770
Food Sci Nutr. 2020 Nov 07;8(12):6513-6527
pubmed: 33312536
Front Microbiol. 2020 Dec 23;11:587782
pubmed: 33424787
Pain Med. 2020 Oct 1;21(10):2366-2372
pubmed: 32488245
Gut. 2021 Mar;70(3):595-605
pubmed: 33051190
Int J Neuropsychopharmacol. 2020 Mar 10;23(1):26-41
pubmed: 31760425
Front Immunol. 2021 Jan 08;11:573158
pubmed: 33488574
World J Gastroenterol. 2019 Sep 28;25(36):5543-5558
pubmed: 31576099
Ann Med. 2019;51(sup1):2-14
pubmed: 30735059
Biochem J. 2017 May 16;474(11):1823-1836
pubmed: 28512250
Nutr Metab (Lond). 2017 Feb 16;14:15
pubmed: 28239402
Mol Nutr Food Res. 2015 Oct;59(10):2066-76
pubmed: 26184884
Nat Rev Immunol. 2019 Jul;19(7):433-447
pubmed: 30874629
Dig Liver Dis. 2018 May;50(5):421-428
pubmed: 29567414
Metabolomics. 2019 Mar 27;15(4):54
pubmed: 30919098
Int J Mol Sci. 2020 Feb 11;21(4):
pubmed: 32054062
J Exp Stroke Transl Med. 2010 Feb 9;3(1):8-18
pubmed: 21423788
Front Immunol. 2018 Apr 27;9:908
pubmed: 29755475
Pain. 2019 Nov;160(11):2589-2602
pubmed: 31219947
Immunol Lett. 2014 Oct;161(2):200-3
pubmed: 24462815
Neuroreport. 2019 Mar 6;30(4):255-261
pubmed: 30640193
Expert Opin Ther Targets. 2013 Sep;17(9):1081-9
pubmed: 23834645
BMC Neurol. 2017 May 11;17(1):88
pubmed: 28490352
Microorganisms. 2020 Aug 16;8(8):
pubmed: 32824364
Br J Nutr. 2014 Jun 14;111(11):1992-9
pubmed: 24521561
J Neurosci. 2021 Mar 31;41(13):2870-2882
pubmed: 33593854
J Formos Med Assoc. 2014 Dec;113(12):921-8
pubmed: 23870713
In Vivo. 2009 Jul-Aug;23(4):621-8
pubmed: 19567398
EBioMedicine. 2019 Aug;46:499-511
pubmed: 31327695
Eur J Nutr. 2020 Aug;59(5):2011-2024
pubmed: 31292752
J Immunol Res. 2014;2014:938576
pubmed: 24741634
BMC Musculoskelet Disord. 2020 Mar 20;21(1):181
pubmed: 32192466
Nutrients. 2020 Aug 31;12(9):
pubmed: 32878326
J Dent Res. 2019 May;98(5):500-509
pubmed: 30894042
Mol Pain. 2014 Nov 18;10:68
pubmed: 25406541
Science. 2016 Nov 4;354(6312):572-577
pubmed: 27811267
Clin J Pain. 2018 Jan;34(1):76-81
pubmed: 28272119
Mediators Inflamm. 2017;2017:9474896
pubmed: 28316379
Eur J Nutr. 2019 Feb;58(1):151-161
pubmed: 29143934